SCHEMBL580509

SCHEMBL580509

CCC(C)(C(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.44
ALDH1A1 P00352 4/20 0.44
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
FFAR3 O14843 2/20 0.39
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
HMGCR P04035 1/20 0.36
CHRM1 P11229 1/20 0.36
TBXA2R P21731 1/20 0.36
ADRA1A P35348 1/20 0.36
TDP1 Q9NUW8 3/20 0.35
KDM4C Q9H3R0 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470836 0.89 TSHR (0.36) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL93137 0.85 ALDH1A1 (0.38) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL2511470 0.83 TSHR (0.36) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL9559385 0.83 KMT2A (0.37) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL7057846 0.83 TSHR (0.36) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL28473558 0.83 ALDH1A1 (0.36) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL11359551 0.83 FFAR3 (0.38) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL26624734 0.81 TSHR (0.35) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL27984219 0.81 ALDH1A1 (0.35) TSHRALDH1A1CYP2D6CYP2C19HIF1A
SCHEMBL28756041 0.79 TSHR (0.37) TSHRALDH1A1CYP2D6CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3694900-B1 NON-AQUEOUS CROSSLINKABLE COMPOSITION ALLNEX NETHERLANDS BV (NL) 2024-01-24 EP claimed
US-11572431-B2 Non-aqueous crosslinkable composition ALLNEX NETHERLANDS B.V. (NL) 2023-02-07 US claimed
CN-113772706-A Preparation method of short column-shaped micron calcium carbonate 广西合山市华纳新材料科技有限公司 2021-12-10 CN claimed
US-20210189050-A1 NON-AQUEOUS CROSSLINKABLE COMPOSITION ALLNEX NETHERLANDS B.V. (NL) 2021-06-24 US claimed
EP-3694900-A1 NON-AQUEOUS CROSSLINKABLE COMPOSITION Allnex Netherlands B.V. (NL) 2020-08-19 EP claimed
CN-111183165-A Non-aqueous crosslinkable composition 湛新荷兰有限公司 2020-05-19 CN claimed
EP-3498747-A1 NON-AQUEOUS CROSSLINKABLE COMPOSITION Allnex Netherlands B.V. (NL) 2019-06-19 EP claimed
EP-3053935-B1 CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION AND APPLICATION OF SAME CHINA PETROLEUM & CHEM CORP (CN) 2019-05-08 EP claimed
WO-2019072433-A1 NON-AQUEOUS CROSSLINKABLE COMPOSITION ALLNEX NETHERLANDS BV (NL) 2019-04-18 WO claimed
US-20190106527-A1 NON-AQUEOUS CROSSLINKABLE COMPOSITION ALLNEX NETHERLANDS BV (NL) 2019-04-11 US claimed
US-9365596-B2 Method for preparing quaternary phosphonium salts MICROVAST POWER SYSTEMS CO., LTD. (CN) 2016-06-14 US claimed
US-20150166587-A1 METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS MICROVAST POWER SYSTEMS CO., LTD. (CN) 2015-06-18 US claimed
EP-0900007-B1 LOW PH ACIDIC COMPOSITIONS BONGARD THOMAS G (US) 2004-02-11 EP claimed
EP-0674233-B1 Recording sheets XEROX CORP (US) 2000-05-24 EP claimed
EP-0284363-B1 2, 6-DIMETHYL OCTYLFORMATE AND AN ATTRACTANT OF TRIBOLIUM CASTANEUM HERBST Japan Tobacco Inc. (JP) 1991-05-22 EP claimed
CN-122029238-A Curable composition and cured product 株式会社钟化 2026-05-12 CN disclosed
US-12319849-B2 Adhesive composition, room-temperature-curable adhesive, and cured object KANEKA CORPORATION (JP) 2025-06-03 US disclosed
US-4128653-A Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives E. R. SQUIBB & SONS, INC. (US) 1978-12-05 US disclosed
US-4086338-A HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1978-04-25 US disclosed
US-4052511-A ANGIOTENSIN CONVERTING ENZYME INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1977-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166587-A1 METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS PHPT1, PHOSPHO1, PTEN TSHR 2677/4885ALDH1A1 4827/4885CYP2D6 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.